[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, reported the disposition of 714 shares of the company's common stock on 09/15/2025 at a price of $25.61 per share. The sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person effective 12/11/2024. After the reported transaction, the reporting person beneficially owned 77,357 shares, held directly. The Form 4 was signed and filed on 09/17/2025, and the filing indicates it was submitted by one reporting person.
Sarah Aebersold, Direttrice Risorse Umane di BioLife Solutions, ha riferito la disposizione di 714 azioni ordinarie della società il 15/09/2025 al prezzo di $25,61 per azione. La vendita è stata effettuata nell'ambito di un piano di negoziazione Rule 10b5-1 adottato dalla persona che presenta la dichiarazione in data 11/12/2024. Dopo l'operazione riportata, la persona che presenta la dichiarazione deteneva direttamente 77.357 azioni. Il Modulo 4 è stato firmato e presentato il 17/09/2025, e la dichiarazione indica che è stato inviato da una sola persona che presenta la dichiarazione.
Sarah Aebersold, Directora de Recursos Humanos de BioLife Solutions, reportó la disposición de 714 acciones comunes de la empresa el 15/09/2025 a un precio de $25.61 por acción. La venta se efectuó bajo un plan de negociación Rule 10b5-1 adoptado por la persona que reporta con efecto desde el 11/12/2024. Tras la operación reportada, la persona que reporta posee beneficiosamente 77,357 acciones, en forma directa. El Formulario 4 fue firmado y presentado el 17/09/2025, y la presentación indica que fue enviada por una sola persona que reporta.
Sarah Aebersold는 BioLife Solutions의 최고 인사 책임자로 회사의 보통주 714주를 2025년 9월 15일에 주당 $25.61의 가격으로 처분했다고 보고했습니다. 이 매각은 보고자에 의해 2024년 12월 11일에 채택된 규칙 10b5-1 거래 계획에 따라 이루어졌습니다. 보고된 거래 후, 보고자는 직접 보유한 77,357주를 유익하게 소유하게 되었습니다. Form 4는 2025년 9월 17일에 서명되어 제출되었으며, 해당 제출은 한 명의 보고자가 제출했음을 나타냅니다.
Sarah Aebersold, Directrice des Ressources Humaines de BioLife Solutions, a déclaré la cession de 714 actions ordinaires de la société au 15/09/2025 au prix de 25,61 $ par action. La vente a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté par la personne déclarant, en vigueur à partir du 11/12/2024. Après la transaction indiquée, la personne déclarant détenait directement 77 357 actions. Le Formulaire 4 a été signé et déposé le 17/09/2025, et le dépôt indique qu'il a été soumis par une seule personne déclarant.
Sarah Aebersold, Chief Human Resources Officer von BioLife Solutions, meldete die Veräußerung von 714 Stammaktien des Unternehmens zum Kurs von 25,61 $ pro Aktie am 15.09.2025. Der Verkauf erfolgte im Rahmen eines Rule-10b5-1-Handelsplans, der von der meldenden Person mit Wirkung zum 11.12.2024 angenommen wurde. Nach der gemeldeten Transaktion hielt die meldende Person direkt 77.357 Aktien als vorteilshaft. Das Formular 4 wurde am 17.09.2025 unterschrieben und eingereicht, wobei angegeben wird, dass es von einer einzigen meldenden Person eingereicht wurde.
ساره أبيرسولد، كبيرة مسؤولي الموارد البشرية في BioLife Solutions، أفادت بتصرف 714 سهماً من أسهم الشركة العادية بسعر 25.61 دولاراً للسهم الواحد في 15/09/2025. تم البيع بموجب خطة تداول Rule 10b5-1 التي اعتمدتها الشخص المبلّغ عنها واعتُمدت اعتباراً من 11/12/2024. بعد الصفقة المذكورة، امتلكت الشخص المبلّغ عنها بشكل مستفيد 77,357 سهماً بشكل مباشر. تم توقيع وتقديم النموذج 4 في 17/09/2025، وتشير الإيداع إلى أنه قدمه شخص واحد مبلّغ عنه.
Sarah Aebersold,BioLife Solutions 的首席人力资源官,报告在 2025/9/15 以每股 $25.61 的价格处置公司普通股 714 股。此次出售是在报告人自 2024/12/11 起生效的 Rule 10b5-1 交易计划 下进行的。报告交易后,报告人直接持有有益的 77,357 股。 Form 4 于 2025/9/17 签署并提交,提交信息显示这是由一名报告人提交。
- Sale executed under a Rule 10b5-1 plan, indicating the trade was pre-planned and compliant with insider trading rules
- Clear, timely disclosure of transaction date, price, and resulting beneficial ownership on Form 4
- Reduction in insider holdings by 714 shares following the sale
Insights
TL;DR: A routine officer sale of 714 shares under a pre-established 10b5-1 plan; modest change to insider holdings.
The transaction is a disclosed, non-derivative sale executed through a Rule 10b5-1 plan, which generally indicates pre-planned dispositions rather than opportunistic trades. The size of the sale (714 shares at $25.61) is small relative to the remaining direct holding of 77,357 shares, so the immediate impact on share supply or valuation is likely negligible. This filing provides clear, timely disclosure consistent with Section 16 reporting obligations.
TL;DR: Proper disclosure and use of a 10b5-1 plan reflect governance compliance; no material red flags in the filing.
The Form 4 documents that the sale was conducted pursuant to a 10b5-1(c) plan established on 12/11/2024, which supports adherence to insider trading policies and provides an audit trail. The filing is specific about the number of shares sold, price, and resulting beneficial ownership, and it is, therefore, a transparent governance disclosure. There is no indication in the document of amendments, joint filings, or derivative activity.
Sarah Aebersold, Direttrice Risorse Umane di BioLife Solutions, ha riferito la disposizione di 714 azioni ordinarie della società il 15/09/2025 al prezzo di $25,61 per azione. La vendita è stata effettuata nell'ambito di un piano di negoziazione Rule 10b5-1 adottato dalla persona che presenta la dichiarazione in data 11/12/2024. Dopo l'operazione riportata, la persona che presenta la dichiarazione deteneva direttamente 77.357 azioni. Il Modulo 4 è stato firmato e presentato il 17/09/2025, e la dichiarazione indica che è stato inviato da una sola persona che presenta la dichiarazione.
Sarah Aebersold, Directora de Recursos Humanos de BioLife Solutions, reportó la disposición de 714 acciones comunes de la empresa el 15/09/2025 a un precio de $25.61 por acción. La venta se efectuó bajo un plan de negociación Rule 10b5-1 adoptado por la persona que reporta con efecto desde el 11/12/2024. Tras la operación reportada, la persona que reporta posee beneficiosamente 77,357 acciones, en forma directa. El Formulario 4 fue firmado y presentado el 17/09/2025, y la presentación indica que fue enviada por una sola persona que reporta.
Sarah Aebersold는 BioLife Solutions의 최고 인사 책임자로 회사의 보통주 714주를 2025년 9월 15일에 주당 $25.61의 가격으로 처분했다고 보고했습니다. 이 매각은 보고자에 의해 2024년 12월 11일에 채택된 규칙 10b5-1 거래 계획에 따라 이루어졌습니다. 보고된 거래 후, 보고자는 직접 보유한 77,357주를 유익하게 소유하게 되었습니다. Form 4는 2025년 9월 17일에 서명되어 제출되었으며, 해당 제출은 한 명의 보고자가 제출했음을 나타냅니다.
Sarah Aebersold, Directrice des Ressources Humaines de BioLife Solutions, a déclaré la cession de 714 actions ordinaires de la société au 15/09/2025 au prix de 25,61 $ par action. La vente a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté par la personne déclarant, en vigueur à partir du 11/12/2024. Après la transaction indiquée, la personne déclarant détenait directement 77 357 actions. Le Formulaire 4 a été signé et déposé le 17/09/2025, et le dépôt indique qu'il a été soumis par une seule personne déclarant.
Sarah Aebersold, Chief Human Resources Officer von BioLife Solutions, meldete die Veräußerung von 714 Stammaktien des Unternehmens zum Kurs von 25,61 $ pro Aktie am 15.09.2025. Der Verkauf erfolgte im Rahmen eines Rule-10b5-1-Handelsplans, der von der meldenden Person mit Wirkung zum 11.12.2024 angenommen wurde. Nach der gemeldeten Transaktion hielt die meldende Person direkt 77.357 Aktien als vorteilshaft. Das Formular 4 wurde am 17.09.2025 unterschrieben und eingereicht, wobei angegeben wird, dass es von einer einzigen meldenden Person eingereicht wurde.